[
  {
    "ts": null,
    "headline": "ANGO Stock Dips Despite Q2 Earnings Beat, Gross Margin Improves",
    "summary": "AngioDynamics reports flat Q2 earnings while revenue increase 8.8% and gross margin expands 170 bps on stronger Med Tech performance.",
    "url": "https://finnhub.io/api/news?id=031c0e74eba9e1e6f1ef172ac833860d7181b14e04b67eb203f27ce0ad9d607b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767805860,
      "headline": "ANGO Stock Dips Despite Q2 Earnings Beat, Gross Margin Improves",
      "id": 138033386,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "AngioDynamics reports flat Q2 earnings while revenue increase 8.8% and gross margin expands 170 bps on stronger Med Tech performance.",
      "url": "https://finnhub.io/api/news?id=031c0e74eba9e1e6f1ef172ac833860d7181b14e04b67eb203f27ce0ad9d607b"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why You Should Add PacBio Stock to Your Portfolio",
    "summary": "PACB is gaining from product development and strong Q3 results, with Revio and Vega driving growth, though longer purchasing cycles remain a risk.",
    "url": "https://finnhub.io/api/news?id=cce700693b4c6b91322d5c55274e3210a25226fc5735c38911908a898fd5589a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767805620,
      "headline": "Here's Why You Should Add PacBio Stock to Your Portfolio",
      "id": 138033388,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "PACB is gaining from product development and strong Q3 results, with Revio and Vega driving growth, though longer purchasing cycles remain a risk.",
      "url": "https://finnhub.io/api/news?id=cce700693b4c6b91322d5c55274e3210a25226fc5735c38911908a898fd5589a"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific (BSX) Just Overtook the 50-Day Moving Average",
    "summary": "Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?",
    "url": "https://finnhub.io/api/news?id=098a23e3c7c3a52bd9fc86fdc451e7ee139f93ded9fb7ceae8f05db2e1ae6187",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767797402,
      "headline": "Boston Scientific (BSX) Just Overtook the 50-Day Moving Average",
      "id": 138033389,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?",
      "url": "https://finnhub.io/api/news?id=098a23e3c7c3a52bd9fc86fdc451e7ee139f93ded9fb7ceae8f05db2e1ae6187"
    }
  },
  {
    "ts": null,
    "headline": "If You Invested $1000 in Boston Scientific 10 Years Ago, This Is How Much You'd Have Now",
    "summary": "Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.",
    "url": "https://finnhub.io/api/news?id=970383a466db441319e121e1952f837cca38ecec112474a1312c251bbd68de5a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767792603,
      "headline": "If You Invested $1000 in Boston Scientific 10 Years Ago, This Is How Much You'd Have Now",
      "id": 138027241,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.",
      "url": "https://finnhub.io/api/news?id=970383a466db441319e121e1952f837cca38ecec112474a1312c251bbd68de5a"
    }
  },
  {
    "ts": null,
    "headline": "We Think Boston Scientific (NYSE:BSX) Can Manage Its Debt With Ease",
    "summary": "Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...",
    "url": "https://finnhub.io/api/news?id=a8cd8c8627ca3d26ee76744a19017910447ca441f98c9b9b9227dafb57fd75c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767783654,
      "headline": "We Think Boston Scientific (NYSE:BSX) Can Manage Its Debt With Ease",
      "id": 138025912,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...",
      "url": "https://finnhub.io/api/news?id=a8cd8c8627ca3d26ee76744a19017910447ca441f98c9b9b9227dafb57fd75c8"
    }
  },
  {
    "ts": null,
    "headline": "Despite Reassurances On Growth, The Market Hasn't Warmed To Stryker",
    "summary": "Stryker outlook: 9%+ FYâ26 growth, margin leverage, and attractive valuation vs. med-tech peers. See why I rate SYK stock a Buy.",
    "url": "https://finnhub.io/api/news?id=2b11314af3888fd0f7052c07cd034563c77da31fc224ffbc6a51031c9c0862cf",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767775540,
      "headline": "Despite Reassurances On Growth, The Market Hasn't Warmed To Stryker",
      "id": 138026429,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1300437730/image_1300437730.jpg?io=getty-c-w1536",
      "related": "BSX",
      "source": "SeekingAlpha",
      "summary": "Stryker outlook: 9%+ FYâ26 growth, margin leverage, and attractive valuation vs. med-tech peers. See why I rate SYK stock a Buy.",
      "url": "https://finnhub.io/api/news?id=2b11314af3888fd0f7052c07cd034563c77da31fc224ffbc6a51031c9c0862cf"
    }
  }
]